All News

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

The FDA reviews NDAs and BLAs to approve medications for sale and marketing in the US with decisions required by the PDUFA date.

The launch of ustekinumab-stba following its FDA approval expands patient access to this therapy with a variety of indications.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

An expert roundtable discussed what consumers and pharmacists should be aware of as compounded versions of glucagon-like peptide-1 receptor agonists continue to proliferate.

Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

Community pharmacists are uniquely positioned to assist with diabetes management using CGM devices.

Educating patients about the nutrition facts label and integrating food pharmacies are examples of pharmacist opportunities.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

Prioritizing preventive measures for high-risk individuals would effectively address half of RSV hospitalizations.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Exidavnemab is a novel monoclonal antibody with disease-modifying potential.

Results highlight promising advancements in novel treatments for patients with HIV-1, including a combination regimen with broadly neutralizing antibodies and long-term data on bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.

Ononogbu discusses research, health equity, and sickle cell advancements.

Approximately 74% of patients with chronic rhinosinusitis with nasal polyps receiving depemokimab across 2 trials did not need additional intervention.

Appellate court addresses application of legal doctrine to the matter.

Treatment with HTD1801 resulted in significant reductions in the hemoglobin A1c level and improved key cardiometabolic and liver parameters.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

As indicated by prior literature, a second dose of intravenous immunoglobulin (IVIG) in patients with Guillain-Barré syndrome increases serum immunoglobulin G levels without improving clinical outcomes.

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

Matthew Zirwas, MD, highlights the discrepancy between perceived and actual usage, citing studies that reveal patients often overestimate their compliance.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

Data privacy and security breaches are a critical concern with AI in health care.

The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.